Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Autoimmune Disease

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2044618

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2044618

Lupus Therapeutics Market Insights, Competitive Landscape, and Market Forecast - 2033

PUBLISHED:
PAGES: 199 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 8495
Printable PDF & Excel (Enterprise License above 5 users)
USD 10600

Add to Cart

Description

Table of Contents

The global Lupus Therapeutics Market is witnessing consistent growth as demand rises for effective treatment options that help manage chronic autoimmune complications and improve patient outcomes. The market is valued at US$ 4.6 Bn in 2026 and is projected to reach US$ 7.1 Bn by 2033, growing at a CAGR of 6.70% during the forecast period. Increasing disease awareness, expanding access to rheumatology care, and continued development of targeted therapies are strengthening market momentum. As lupus often requires lifelong treatment, healthcare providers are focusing on therapies that reduce flare-ups, protect organs, and support better long-term disease control.

Market Insights

Lupus is a multifaceted autoimmune disorder in which the immune system attacks healthy tissues, leading to inflammation and damage across different organs. The disease can appear in several forms, including systemic lupus erythematosus, cutaneous lupus erythematosus, drug-induced lupus, neonatal lupus, and lupus nephritis. Among these, systemic lupus erythematosus remains a major area of treatment demand because it can affect multiple organ systems and requires continuous monitoring.

The market is shifting from broad symptom management toward more targeted and personalized treatment approaches. Corticosteroids, antimalarials, immunosuppressants, and nonsteroidal anti-inflammatory drugs continue to play an important role in standard care. However, biologics, B-cell inhibitors, and calcineurin inhibitors are gaining attention as physicians seek therapies that offer better disease control with reduced long-term toxicity. This changing treatment landscape is creating new opportunities for companies focused on autoimmune and inflammatory disease portfolios.

Drivers

A major driver for the Lupus Therapeutics Market is the growing prevalence of autoimmune disorders and the increasing number of patients seeking specialist care. Greater awareness among patients and physicians is helping improve diagnosis rates, especially in cases where symptoms overlap with other chronic inflammatory conditions. Early diagnosis enables timely treatment, reducing the risk of severe disease progression and organ involvement.

Another important driver is the rising need to reduce dependence on long-term corticosteroid use. While corticosteroids remain effective for controlling inflammation, prolonged use can be associated with significant side effects. This has encouraged the adoption of steroid-sparing therapies and targeted drug classes. Advancements in biologics and immunology research are also supporting the development of therapies designed to address specific immune pathways involved in lupus.

Business Opportunity

The market offers strong business opportunities for pharmaceutical manufacturers, biotechnology companies, specialty pharmacies, and healthcare service providers. Companies developing differentiated therapies for lupus nephritis, systemic lupus erythematosus, and refractory lupus cases can gain a competitive advantage. Products that demonstrate improved safety, durable response, convenient dosing, and compatibility with combination therapy are likely to attract greater physician and patient interest.

Specialty pharmacies are expected to play an increasingly important role in supporting access to advanced therapies. These channels can provide patient education, adherence programs, reimbursement assistance, and treatment monitoring support. Online pharmacies are also gaining relevance as patients seek convenient access to chronic disease medications. In addition, collaborations between drug developers, academic centers, and patient advocacy groups can help improve clinical trial recruitment and accelerate therapy innovation.

Region Analysis

North America is expected to hold a significant position in the Lupus Therapeutics Market due to advanced healthcare infrastructure, high awareness of autoimmune diseases, and strong adoption of innovative treatments. The region also benefits from the presence of major pharmaceutical companies, active clinical research, and well-established specialty care networks.

Europe represents another important market, supported by structured healthcare systems, increasing use of biologics, and growing focus on autoimmune disease management. Asia Pacific is likely to show notable growth potential as diagnostic capabilities improve and access to specialty clinics expands. Rising healthcare expenditure, increasing awareness, and a large patient population are expected to support market development across key countries in the region. Latin America and the Middle East & Africa are also witnessing gradual improvement as healthcare systems expand access to chronic disease therapies and specialist consultation.

Market Outlook

The future of the Lupus Therapeutics Market will be shaped by innovation, patient-centered care, and improved access to advanced treatment options. As clinical understanding of lupus continues to evolve, therapy selection is becoming more individualized based on disease type, severity, organ involvement, and patient response. This trend is expected to increase demand for targeted therapies that can deliver consistent disease control and reduce complications.

Pharmaceutical companies are likely to focus on clinical differentiation, real-world evidence, and expanded indications to strengthen market presence. Patient support programs, affordability initiatives, and improved distribution networks will also be important for broader therapy adoption. With lupus requiring long-term management, stakeholders that can combine effective treatment with adherence support and specialist care coordination will be well positioned for future growth.

Key Players

The Lupus Therapeutics Market includes several global companies investing in autoimmune disease treatment, biologics, immunology research, and specialty therapeutics. Key players include:

  • GSK plc
  • AstraZeneca PLC
  • Aurinia Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Novartis AG
  • Eli Lilly and Company
  • Bristol Myers Squibb Company
  • AbbVie Inc.
  • Amgen Inc.
  • Biogen Inc.
  • Johnson & Johnson
  • UCB S.A.
  • Viatris Inc.

Segmentation

By Disease Type

  • Systemic Lupus Erythematosus
  • Cutaneous Lupus Erythematosus
  • Drug-induced Lupus
  • Neonatal Lupus
  • Lupus Nephritis
  • Others

By Drug Class

  • Corticosteroids
  • Antimalarials
  • Immunosuppressants
  • Biologics
  • Nonsteroidal Anti-inflammatory Drugs
  • B-cell Inhibitors
  • Calcineurin Inhibitors
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Specialty Pharmacies
  • Online Pharmacies

By End User

  • Hospitals
  • Specialty Clinics
  • Rheumatology Clinics
  • Dermatology Clinics
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Lupus Therapeutics Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global Lupus Therapeutics Market Outlook, 2020 - 2033

  • 3.1. Global Lupus Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033
    • 3.1.1. Systemic Lupus Erythematosus
    • 3.1.2. Cutaneous Lupus Erythematosus
    • 3.1.3. Drug-induced Lupus
    • 3.1.4. Neonatal Lupus
    • 3.1.5. Lupus Nephritis
    • 3.1.6. Others
  • 3.2. Global Lupus Therapeutics Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 3.2.1. Corticosteroids
    • 3.2.2. Antimalarials
    • 3.2.3. Immunosuppressants
    • 3.2.4. Biologics
    • 3.2.5. Nonsteroidal Anti-inflammatory Drugs
    • 3.2.6. B-cell Inhibitors
    • 3.2.7. Calcineurin Inhibitors
    • 3.2.8. Others
  • 3.3. Global Lupus Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 3.3.1. Hospital Pharmacies
    • 3.3.2. Retail Pharmacies
    • 3.3.3. Specialty Pharmacies
    • 3.3.4. Online Pharmacies
  • 3.4. Global Lupus Therapeutics Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 3.4.1. Hospitals
    • 3.4.2. Specialty Clinics
    • 3.4.3. Rheumatology Clinics
    • 3.4.4. Dermatology Clinics
    • 3.4.5. Ambulatory Surgical Centers
    • 3.4.6. Others
  • 3.5. Global Lupus Therapeutics Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.5.1. North America
    • 3.5.2. Europe
    • 3.5.3. Asia Pacific
    • 3.5.4. Latin America
    • 3.5.5. Middle East & Africa

4. North America Lupus Therapeutics Market Outlook, 2020 - 2033

  • 4.1. North America Lupus Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033
    • 4.1.1. Systemic Lupus Erythematosus
    • 4.1.2. Cutaneous Lupus Erythematosus
    • 4.1.3. Drug-induced Lupus
    • 4.1.4. Neonatal Lupus
    • 4.1.5. Lupus Nephritis
    • 4.1.6. Others
  • 4.2. North America Lupus Therapeutics Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 4.2.1. Corticosteroids
    • 4.2.2. Antimalarials
    • 4.2.3. Immunosuppressants
    • 4.2.4. Biologics
    • 4.2.5. Nonsteroidal Anti-inflammatory Drugs
    • 4.2.6. B-cell Inhibitors
    • 4.2.7. Calcineurin Inhibitors
    • 4.2.8. Others
  • 4.3. North America Lupus Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 4.3.1. Hospital Pharmacies
    • 4.3.2. Retail Pharmacies
    • 4.3.3. Specialty Pharmacies
    • 4.3.4. Online Pharmacies
  • 4.4. North America Lupus Therapeutics Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 4.4.1. Hospitals
    • 4.4.2. Specialty Clinics
    • 4.4.3. Rheumatology Clinics
    • 4.4.4. Dermatology Clinics
    • 4.4.5. Ambulatory Surgical Centers
    • 4.4.6. Others
  • 4.5. North America Lupus Therapeutics Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.5.1. U.S. Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 4.5.2. U.S. Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 4.5.3. U.S. Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 4.5.4. U.S. Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 4.5.5. Canada Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 4.5.6. Canada Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 4.5.7. Canada Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 4.5.8. Canada Lupus Therapeutics Market Outlook, by End User, 2020-2033
  • 4.6. BPS Analysis/Market Attractiveness Analysis

5. Europe Lupus Therapeutics Market Outlook, 2020 - 2033

  • 5.1. Europe Lupus Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033
    • 5.1.1. Systemic Lupus Erythematosus
    • 5.1.2. Cutaneous Lupus Erythematosus
    • 5.1.3. Drug-induced Lupus
    • 5.1.4. Neonatal Lupus
    • 5.1.5. Lupus Nephritis
    • 5.1.6. Others
  • 5.2. Europe Lupus Therapeutics Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 5.2.1. Corticosteroids
    • 5.2.2. Antimalarials
    • 5.2.3. Immunosuppressants
    • 5.2.4. Biologics
    • 5.2.5. Nonsteroidal Anti-inflammatory Drugs
    • 5.2.6. B-cell Inhibitors
    • 5.2.7. Calcineurin Inhibitors
    • 5.2.8. Others
  • 5.3. Europe Lupus Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Retail Pharmacies
    • 5.3.3. Specialty Pharmacies
    • 5.3.4. Online Pharmacies
  • 5.4. Europe Lupus Therapeutics Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 5.4.1. Hospitals
    • 5.4.2. Specialty Clinics
    • 5.4.3. Rheumatology Clinics
    • 5.4.4. Dermatology Clinics
    • 5.4.5. Ambulatory Surgical Centers
    • 5.4.6. Others
  • 5.5. Europe Lupus Therapeutics Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.5.1. Germany Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 5.5.2. Germany Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 5.5.3. Germany Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 5.5.4. Germany Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 5.5.5. Italy Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 5.5.6. Italy Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 5.5.7. Italy Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 5.5.8. Italy Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 5.5.9. France Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 5.5.10. France Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 5.5.11. France Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 5.5.12. France Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 5.5.13. U.K. Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 5.5.14. U.K. Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 5.5.15. U.K. Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 5.5.16. U.K. Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 5.5.17. Spain Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 5.5.18. Spain Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 5.5.19. Spain Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 5.5.20. Spain Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 5.5.21. Russia Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 5.5.22. Russia Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 5.5.23. Russia Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 5.5.24. Russia Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 5.5.25. Rest of Europe Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 5.5.26. Rest of Europe Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 5.5.27. Rest of Europe Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 5.5.28. Rest of Europe Lupus Therapeutics Market Outlook, by End User, 2020-2033
  • 5.6. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Lupus Therapeutics Market Outlook, 2020 - 2033

  • 6.1. Asia Pacific Lupus Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033
    • 6.1.1. Systemic Lupus Erythematosus
    • 6.1.2. Cutaneous Lupus Erythematosus
    • 6.1.3. Drug-induced Lupus
    • 6.1.4. Neonatal Lupus
    • 6.1.5. Lupus Nephritis
    • 6.1.6. Others
  • 6.2. Asia Pacific Lupus Therapeutics Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 6.2.1. Corticosteroids
    • 6.2.2. Antimalarials
    • 6.2.3. Immunosuppressants
    • 6.2.4. Biologics
    • 6.2.5. Nonsteroidal Anti-inflammatory Drugs
    • 6.2.6. B-cell Inhibitors
    • 6.2.7. Calcineurin Inhibitors
    • 6.2.8. Others
  • 6.3. Asia Pacific Lupus Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail Pharmacies
    • 6.3.3. Specialty Pharmacies
    • 6.3.4. Online Pharmacies
  • 6.4. Asia Pacific Lupus Therapeutics Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 6.4.1. Hospitals
    • 6.4.2. Specialty Clinics
    • 6.4.3. Rheumatology Clinics
    • 6.4.4. Dermatology Clinics
    • 6.4.5. Ambulatory Surgical Centers
    • 6.4.6. Others
  • 6.5. Asia Pacific Lupus Therapeutics Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.5.1. China Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 6.5.2. China Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 6.5.3. China Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 6.5.4. China Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 6.5.5. Japan Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 6.5.6. Japan Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 6.5.7. Japan Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 6.5.8. Japan Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 6.5.9. South Korea Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 6.5.10. South Korea Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 6.5.11. South Korea Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 6.5.12. South Korea Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 6.5.13. India Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 6.5.14. India Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 6.5.15. India Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 6.5.16. India Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 6.5.17. Southeast Asia Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 6.5.18. Southeast Asia Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 6.5.19. Southeast Asia Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 6.5.20. Southeast Asia Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 6.5.21. Rest of SAO Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 6.5.22. Rest of SAO Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 6.5.23. Rest of SAO Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 6.5.24. Rest of SAO Lupus Therapeutics Market Outlook, by End User, 2020-2033
  • 6.6. BPS Analysis/Market Attractiveness Analysis

7. Latin America Lupus Therapeutics Market Outlook, 2020 - 2033

  • 7.1. Latin America Lupus Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033
    • 7.1.1. Systemic Lupus Erythematosus
    • 7.1.2. Cutaneous Lupus Erythematosus
    • 7.1.3. Drug-induced Lupus
    • 7.1.4. Neonatal Lupus
    • 7.1.5. Lupus Nephritis
    • 7.1.6. Others
  • 7.2. Latin America Lupus Therapeutics Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 7.2.1. Corticosteroids
    • 7.2.2. Antimalarials
    • 7.2.3. Immunosuppressants
    • 7.2.4. Biologics
    • 7.2.5. Nonsteroidal Anti-inflammatory Drugs
    • 7.2.6. B-cell Inhibitors
    • 7.2.7. Calcineurin Inhibitors
    • 7.2.8. Others
  • 7.3. Latin America Lupus Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies
    • 7.3.3. Specialty Pharmacies
    • 7.3.4. Online Pharmacies
  • 7.4. Latin America Lupus Therapeutics Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 7.4.1. Hospitals
    • 7.4.2. Specialty Clinics
    • 7.4.3. Rheumatology Clinics
    • 7.4.4. Dermatology Clinics
    • 7.4.5. Ambulatory Surgical Centers
    • 7.4.6. Others
  • 7.5. Latin America Lupus Therapeutics Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.5.1. Brazil Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 7.5.2. Brazil Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 7.5.3. Brazil Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 7.5.4. Brazil Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 7.5.5. Mexico Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 7.5.6. Mexico Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 7.5.7. Mexico Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 7.5.8. Mexico Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 7.5.9. Argentina Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 7.5.10. Argentina Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 7.5.11. Argentina Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 7.5.12. Argentina Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 7.5.13. Rest of LATAM Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 7.5.14. Rest of LATAM Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 7.5.15. Rest of LATAM Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 7.5.16. Rest of LATAM Lupus Therapeutics Market Outlook, by End User, 2020-2033
  • 7.6. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Lupus Therapeutics Market Outlook, 2020 - 2033

  • 8.1. Middle East & Africa Lupus Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033
    • 8.1.1. Systemic Lupus Erythematosus
    • 8.1.2. Cutaneous Lupus Erythematosus
    • 8.1.3. Drug-induced Lupus
    • 8.1.4. Neonatal Lupus
    • 8.1.5. Lupus Nephritis
    • 8.1.6. Others
  • 8.2. Middle East & Africa Lupus Therapeutics Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 8.2.1. Corticosteroids
    • 8.2.2. Antimalarials
    • 8.2.3. Immunosuppressants
    • 8.2.4. Biologics
    • 8.2.5. Nonsteroidal Anti-inflammatory Drugs
    • 8.2.6. B-cell Inhibitors
    • 8.2.7. Calcineurin Inhibitors
    • 8.2.8. Others
  • 8.3. Middle East & Africa Lupus Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Specialty Pharmacies
    • 8.3.4. Online Pharmacies
  • 8.4. Middle East & Africa Lupus Therapeutics Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 8.4.1. Hospitals
    • 8.4.2. Specialty Clinics
    • 8.4.3. Rheumatology Clinics
    • 8.4.4. Dermatology Clinics
    • 8.4.5. Ambulatory Surgical Centers
    • 8.4.6. Others
  • 8.5. Middle East & Africa Lupus Therapeutics Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.5.1. GCC Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 8.5.2. GCC Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 8.5.3. GCC Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 8.5.4. GCC Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 8.5.5. South Africa Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 8.5.6. South Africa Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 8.5.7. South Africa Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 8.5.8. South Africa Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 8.5.9. Egypt Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 8.5.10. Egypt Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 8.5.11. Egypt Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 8.5.12. Egypt Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 8.5.13. Nigeria Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 8.5.14. Nigeria Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 8.5.15. Nigeria Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 8.5.16. Nigeria Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 8.5.17. Rest of Middle East Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 8.5.18. Rest of Middle East Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 8.5.19. Rest of Middle East Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 8.5.20. Rest of Middle East Lupus Therapeutics Market Outlook, by End User, 2020-2033
  • 8.6. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. GSK plc
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. AstraZeneca PLC
    • 9.4.3. Aurinia Pharmaceuticals Inc.
    • 9.4.4. F. Hoffmann-La Roche Ltd.
    • 9.4.5. Pfizer Inc.
    • 9.4.6. Sanofi S.A.
    • 9.4.7. Novartis AG
    • 9.4.8. Eli Lilly and Company
    • 9.4.9. Bristol Myers Squibb Company
    • 9.4.10. AbbVie Inc.
    • 9.4.11. Amgen Inc.
    • 9.4.12. Biogen Inc.
    • 9.4.13. Johnson & Johnson
    • 9.4.14. UCB S.A.
    • 9.4.15. Viatris Inc.

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!